Trial News & Events

ALS Researchers Appear on “The Doctors”

NEALS Co-Chair Merit Cudkowicz, MD, MSc (Massachusetts General Hospital) and NEALS member Robert Baloh, MD, PhD (Cedars-Sinai) appeared on an episode of "The Doctors" with PALS Nanci Ryder, a celebrity publicist who opened up about her ALS diagnosis. Check your local listings for show times, and view a short clip and article about the episode here.…

PALS Speaks to Congress about ALS Research

Attorney and PALS Michael Gollin spoke to Congress November 18th about how they can help change the balance of risks to favor successful innovation in ALS research, and why they should adopt the MODERN Cures Act. You can read Michael’s full testimony at the MODDERN Cures Act Briefing here.…

Dr. Cudkowicz Appears on “CBS This Morning”

NEALS Co-Chair Merit Cudkowicz, MD, MSc (Massachusetts General Hospital) appeared on “CBS This Morning” to discuss donations from the ALS ice bucket challenge, and the ways that the initiative has already aided researchers in identifying new targets for treatment. You can view the full piece here.…

13th Annual NEALS Meeting

This year's annual NEALS meeting took place October 22nd-24th in Clearwater Beach, FL.

Cytokinetics provides update on Tirasemtiv

Cytokinetics, Inc announced that it has completed its review of results from BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv ALS) and has concluded that the effects observed on Slow Vital Capacity (SVC) in PALS treated with tirasemtiv are potentially clinically meaningful. As a result, Cytokinetics has initiated planning for a potential Phase III clinical trial of tirasemtiv that could begin in 2015. Click here to read more about this update.…

Genervon Phase IIa Study of GM604 Completed

Genervon Biopharmaceuticals, LLC announced that it has completed the analysis of its Phase 2a double blinded, randomized, placebo controlled clinical trials of Amyotrophic Lateral Sclerosis (NCT01854294) and Parkinson’s disease (NCT 01850381) for its drug candidate GM604. "The two trials were designed to determine whether a six-dose treatment of GM6 would begin the process of disease modification. Genervon was told not to expect any statistically significant drug effects because of the small number of patients in both trials, but was delighted to find that both clinical and biomarker data in the ALS and the PD…

Phase II Mexiletine Study Completed

A phase II, 60 patient NEALS-sponsored multicenter randomized controlled trial of Mexiletine in the treatment of ALS was recently completed.